Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Methylphenidate for ADHD rejected from the WHO Essential Medicines List due to uncertainties in benefit-harm profile

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Assessment of assumptions of statistical analysis methods in randomised clinical trials: the what and how

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Blinding in randomised clinical trials of psychological interventions: a retrospective study of published trial reports

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Considerations on the strengths and limitations of using disease-related mortality as an outcome in clinical research

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  4. Seeing is believing – the problem of blinding in psychological research

    Publikation: Bidrag til tidsskriftLetterForskning

  1. The effects of adding quinolones to beta-lactam antibiotics for sepsis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Vitamin D supplementation for chronic liver diseases in adults

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Attention deficit hyperactivity disorder (ADHD) is a common psychiatric disorder with estimated global prevalence rates between 3% and 5% in children and 2.5% in adults, depending on the classification system used. The psychostimulant methylphenidate is one of the most frequently used medications for ADHD. In this analysis article we describe shortly the evidence in the field, an application for inclusion of methylphenidate on the WHO Model List of Essential Medicines, the comments raised to the application and the WHO Expert Committee's decision. The application of getting methylphenidate on the WHO list was overzealous in reporting potential benefits, without highlighting key uncertainties and harms. Decisions encompassing medicines candidate to the WHO Model List should not be based on speculation about potential benefits and should fully incorporate areas of uncertainties. Even though methylphenidate has been used for over 60 years, the evidence concerning the benefits of this medication in children, adolescents and adults with ADHD is uncertain. The decision of the committee was to not include methylphenidate in the WHO Model List of Essential Medicines 'due to uncertainties in the estimates of benefit, and concerns regarding the quality and limitations of the available evidence for both benefit and harm'.

OriginalsprogEngelsk
TidsskriftBMJ Evidence-Based Medicine
Vol/bind26
Udgave nummer4
Sider (fra-til)172-175
Antal sider4
ISSN1356-5524
DOI
StatusUdgivet - 1 aug. 2021

Bibliografisk note

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

ID: 59736352